Answer extracted from the Morning Brew Daily podcast — listen to the full episode below.
What is RasenQ and why is its FDA approval considered a breakthrough for pancreatic cancer?
RasenQ, developed by Revolution Medicines, is the first drug to successfully target the KRAS protein—a driver of nearly all pancreatic cancers that was previously considered undruggable due to its smooth surface. In late-stage trials, patients on RasenQ lived over 13 months on average compared to 6.7 months for those receiving standard chemotherapy. The FDA approved it this week, marking a fundamental shift in how pancreatic cancer can be treated.
For decades, the KRAS protein remained a frustrating puzzle for oncologists. Its shape made it nearly impossible to bind pharmaceutical molecules to it—hence the label "undruggable." Pancreatic cancer, which affects over 60,000 people annually in the United States, has long carried one of the poorest survival rates among major cancers, with KRAS mutations present in approximately 90% of all pancreatic cancer cases.
Revolution Medicines' breakthrough lies in a novel molecular approach that finally cracked this obstacle. As detailed in the episode, the drug's ability to bind to KRAS represents years of targeted research. This single approval opens the door to an entirely new class of cancer therapeutics that had been written off as impossible.
The clinical evidence is striking. In the phase 2b study that led to FDA approval, the 13-month average survival extension doubled the historical baseline for pancreatic cancer patients. This is not a marginal improvement—it signals a potential paradigm shift in how the disease is managed. The sticker price, at nearly $40,000 per month or approximately $478,000 annually, reflects both the complexity of the drug's development and the market's assessment of its clinical value.
Financial markets have already reacted decisively. Revolution Medicines shares are up nearly 180% in 2025, and analysts project RasenQ will generate more than $9 billion in annual sales by 2032. For oncology investors and patients alike, this approval represents proof that previously untargatable proteins can be addressed with enough ingenuity and investment, potentially unlocking treatments for other historically difficult-to-drug cancers.
KRAS is a protein that, when mutated, drives the growth of multiple cancer types, most notably pancreatic cancer. It was considered "undruggable" because its smooth molecular surface lacked the binding pockets that conventional drug molecules could attach to, making it extremely difficult to inhibit pharmacologically until RasenQ's novel mechanism overcame this barrier.
For more context on how this breakthrough fits into the broader biotech and pharma landscape, listen to Morning Brew Daily for the full episode discussion, which also explores the broader implications of targeted cancer therapies and the timelines for patient access to this new treatment.
See also
What is Shein's new strategic direction after its fast fashion model stalled?
Shein is pivoting to become what it calls "the Amazon Web Services of the fashion industry," aiming to serve as the back-end infrastructure for other retailers and brands.
What caused Shein's valuation to collapse from $100 billion to $27 billion ahead of its Hong Kong IPO?
Shein's valuation fell from a $100 billion peak in 2022 to $27 billion at its Hong Kong Stock Exchange IPO because of two main factors: the repeal of the de minimis exemption and stalled revenue growth, swinging from $3.4 billion in profit to an operating loss.
Why is the Jackson Hole symposium 2025 so closely watched by markets?
Fed Chair Kevin Warsh has been unusually opaque since taking over, leaving Wall Street in the dark about future rate decisions. His July press conference triggered market turmoil, with the Dow falling 1.6% over 840 points.
Key takeaways
- RasenQ is the first-ever drug to successfully inhibit the KRAS protein, which drives 90% of pancreatic cancers and was previously considered undruggable.
- Patients treated with RasenQ survived over 13 months on average versus 6.7 months with standard chemotherapy, nearly doubling survival rates in trials.
- Revolution Medicines' shares have surged 180% in 2025, and RasenQ is projected to generate over $9 billion in annual sales by 2032.
- At $478,000 per year, RasenQ's price reflects both its development complexity and its potential to transform treatment of a disease historically marked by poor prognosis.